report-bg

Liposome Drug Delivery Market Analysis by Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B); Technology (Stealth, Non-PEGylated, DepoFoam Liposome Technology); Application (Fungal Diseases, Pain Management, Cancer Therapy, Viral Vaccines, Photodynamic Therapy) – Global Supply & Demand Analysis & Opportunity Outlook 2023 – 2035

Buy Now Report ID: 4073 | Published Date: May 01, 2023
  1. Market Definition
    1. Definition
    2. Market Segmentation
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
    3. Secondary Research
  4. Executive Summary – Global Liposome Drug Delivery Market
  5. Market Dynamics
    1. Drivers
    2. Challenges
    3. Trends
    4. Opportunities
  6. Pipeline Analysis
  7. Clinically Marketed Liposome Drugs
  8. Regulatory Scenario Assessment
  9. Analysis on Lipid Nanoparticles
  10. Competitive Landscape
    1. Market Share Analysis, 2021
    2. Company Profiles
      1. Pharmaceutical Formulation Manufacturers
        1. Spectrum Pharmaceuticals, Inc.
        2. Gilead Sciences, Inc.
        3. Celsion Corporation
        4. Ipsen Pharma
        5. Pacira Pharmaceuticals, Inc.
        6. Novartis AG
        7. CordenPharma International
        8. FUJIFILM Toyama Chemical Co., Ltd.
        9. Takeda Pharmaceutical Company Limited
        10. Johnson & Johnson Services, Inc.
        11. Astellas Pharma Inc.
        12. Elan Pharmaceuticals (Perrigo Company plc)
        13. Merrimack Pharmaceuticals, Inc.
        14. Janssen Pharmaceuticals, Inc.
      2. Raw Material Manufacturers
        1. NIPPON FINE CHEMICAL CO., LTD.
        2. Sonic Biochem Extractions Pvt. Ltd.
        3. Croda International Plc
        4. Lipoid GmbH
        5. Hashimoto Electronic Industry Co., LTD
  11. Global Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
        1. Liposomal Doxorubicin, 2021-2031F (USD Million)
        2. Liposomal Paclitaxel, 2021-2031F (USD Million)
        3. Liposomal Amphotericin, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      2. Technology
        1. Stealth Liposome Technology, 2021-2031F (USD Million)
        2. Non-PEGylated Liposome Technology, 2021-2031F (USD Million)
        3. DepoFoam Liposome Technology, 2021-2031F (USD Million)
      3. Application
        1. Fungal Diseases, 2021-2031F (USD Million)
        2. Pain Management, 2021-2031F (USD Million)
        3. Cancer Therapy, 2021-2031F (USD Million)
        4. Viral Vaccines, 2021-2031F (USD Million)
        5. Photodynamic Therapy, 2021-2031F (USD Million)
        6. Others, 2021-2031F (USD Million)
      4. Region
        1. North America, 2021-2031F (USD Million)
        2. Europe, 2021-2031F (USD Million)
        3. Asia Pacific, 2021-2031F (USD Million)
        4. Latin America, 2021-2031F (USD Million)
        5. Middle East & Africa, 2021-2031F (USD Million)
  12. North America Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
        1. Liposomal Doxorubicin, 2021-2031F (USD Million)
        2. Liposomal Paclitaxel, 2021-2031F (USD Million)
        3. Liposomal Amphotericin, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      2. Technology
        1. Stealth Liposome Technology, 2021-2031F (USD Million)
        2. Non-PEGylated Liposome Technology, 2021-2031F (USD Million)
        3. DepoFoam Liposome Technology, 2021-2031F (USD Million)
      3. Application
        1. Fungal Diseases, 2021-2031F (USD Million)
        2. Pain Management, 2021-2031F (USD Million)
        3. Cancer Therapy, 2021-2031F (USD Million)
        4. Viral Vaccines, 2021-2031F (USD Million)
        5. Photodynamic Therapy, 2021-2031F (USD Million)
        6. Others, 2021-2031F (USD Million)
      4. Country
        1. United States, 2021-2031F (USD Million)
        2. Canada, 2021-2031F (USD Million)
  13. Europe Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
      2. Technology
      3. Application
      4. Country
        1. Germany, 2021-2031F (USD Million)
        2. United Kingdom, 2021-2031F (USD Million)
        3. France, 2021-2031F (USD Million)
        4. Italy, 2021-2031F (USD Million)
        5. Spain, 2021-2031F (USD Million)
        6. Rest of Europe, 2021-2031F (USD Million)
  14. Asia Pacific Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
      2. Technology
      3. Application
      4. Country
        1. China, 2021-2031F (USD Million)
        2. India, 2021-2031F (USD Million)
        3. Japan, 2021-2031F (USD Million)
        4. Australia, 2021-2031F (USD Million)
        5. New Zealand, 2021-2031F (USD Million)
        6. Rest of APAC, 2021-2031F (USD Million)
  15. Latin America Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
      2. Technology
      3. Application
      4. Country
        1. Brazil, 2021-2031F (USD Million)
        2. Mexico, 2021-2031F (USD Million)
        3. Rest of LATAM, 2021-2031F (USD Million)
  16. Middle East & Africa Liposome Drug Delivery Market
    1. Market Overview
    2. Market Size (2021-2031)
    3. Market Segmentation by:
      1. Product
      2. Technology
      3. Application
      4. Country
        1. GCC, 2021-2031F (USD Million)
        2. South Africa, 2021-2031F (USD Million)
        3. Rest of MEA, 2021-2031F (USD Million)

Global Liposome Drug Delivery Market Size, Forecast, and Trend Highlights Over 2023 – 2035

Liposome Drug Delivery Market size is estimated to reach ~USD 10 billion by the end of 2035 by growing at a CAGR of ~9% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of liposome drug delivery was ~USD 5 billion. The growth of this market can be attributed to the growing demand for effective and efficient therapeutics considering the growing cases of chronic disease all over the world. Also, liposome-based drug delivery methods contain certain advantages as compared to other delivery systems. As a result, drugs are encapsulated into liposomes for effective delivery. According to World Health Organization, 41 million people lose their life owing to chronic disease every year which is equivalent to 74% of death globally. 

In addition, increasing advances in liposomal drug delivery methods owing to new investments and ongoing R&D activities, product launches, mergers and acquisitions, and collaborations among major market players, are driving the growth of liposomal drug delivery expected to drive further growth of the market. Moreover, various government authorities have been seen offering funds and investments for the research and development activities of the liposome drug delivery market. For instance, in 2019, the NIH awarded researchers at the University of Massachusetts Amherst a USD 1.7 million grant to develop new liposome-based vaccine delivery systems. 


RN
/admin/report_image/Liposome Drug Delivery Market.PNG
Get more information on this report: Request Free Sample PDF

Global Liposome Drug Delivery Market: Key Insights

Base Year

2022

Forecast Year

2023 – 2035

CAGR

~9%

Base Year Market Size (2022)

~USD 5 billion

Forecast Year Market Size (2035)

~USD 10 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

 


Global Liposome Drug Delivery Market: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Rising Prevalence of Cancer Globally – Liposome drug delivery is widely used in the treatment of cancer owing to its wide range of advantages and properties. In 2020, 10 million people died out of cancer all over the globe and 5 million new cases were recorded. 
  • Growing Significance of Liposomes as a Drug Delivery System - Owing to the importance of liposomes in drug delivery, numerous studies, and clinical trials are ongoing and positive results from these sources are expected to continue to have a positive impact on the growth of the market under study. According to the study "Inhaled Liposomal Antimicrobial Delivery in Pulmonary Infections" published in July 2020, the use of inhaled liposomal antimicrobial therapy in pulmonary infections resulted in the antimicrobial agent targeting the infective organisms at the site of infection, thereby increasing the intracellular antibiotic concentration. Reduces drug toxicity and improves tolerability. 
  • Growing Presence of Chronic Diseases - As the prevalence of chronic diseases such as diabetes, cardiovascular disease, cancer, and others increases worldwide, the demand for effective therapeutics is increasing, which is expected to boost the growth of the liposomal drug delivery market. For instance, according to the World Health Organization, cardiovascular disease is the leading cause of death worldwide, killing approximately 17.9 million people in 2019. 
  • Growing Acquisition and R&D Activities – Increasing support and funds by the government authorities on research and development activities in the liposome drug delivery field is expected to drive the growth of this market in the forecast period. In 2018, the EU awarded a USD 6 million grant to a consortium of European universities and companies to develop new liposome-based drug delivery systems to treat pulmonary diseases. 

Challenges

  • High Cost of Development of the Drug Delivery System – Liposome drug delivery can be expensive and can limit access for patients who cannot afford it. This can be a particularly big challenge in developing countries with limited healthcare budgets. 
  • Limited Clinical Data
  • Competition from Drug Delivery Technologies


Global Liposome Drug Delivery Market Segmentation

 

The global liposome drug delivery market is segmented and analyzed for demand and supply by application into fungal diseases, pain management, cancer therapy, viral vaccines, photodynamic therapy, and others. Out of these, the cancer therapy segment is anticipated to hold the largest market share by the end of 2035. This can be attributed to the high prevalence of cancer and the growing demand for advanced therapeutics. Over the years, the prevalence of cancer has been seen to increase rapidly which is expected to drive the growth of the cancer therapy segment. As cancer is one of the diseases which attracts more attention from the R&D owing to its high prevalence and seriousness, this segment is anticipated to grow in the upcoming times. According to a report, there were approximately 19.3 million new cancer diagnoses worldwide in 2020, with breast cancer being the most common cancer, followed by lung cancer. 

The global market is segmented and analyzed for demand and supply by-products into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Out of these, the liposomal doxorubicin segment is anticipated to hold the largest market share by the end of 2035. This segment includes liposomes that are used to deliver the chemotherapy drug doxorubicin. Liposomal doxorubicin is effective in treating certain types of cancer, such as ovarian and breast cancer.

Our in-depth analysis of the global liposome drug delivery market includes the following segments:

 

        By Product

  • Liposomal Doxorubicin
  •  Liposomal Paclitaxel
  •  Liposomal Amphotericin B
  • Others

        By Technology

  • Stealth
  • Non-PEGylated
  •  DepoFoam Liposome Technology

        By Application

  • Fungal Diseases
  • Pain Management
  •  Cancer Therapy
  • Viral Vaccines
  •  Photodynamic Therapy
  • Others

 


Global Liposome Drug Delivery Market Regional Synopsis

regional-synopsis

The market in North America is projected to garner the largest revenue by the end of 2035. The growth of the market in the region can primarily be attributed to the increasing prevalence of cancer in the region, followed by the surge in government initiatives that promote research and development for cancer drugs and drug delivery systems, along with the surge in healthcare expenditure in the region. According to the statistics by the National Cancer Institute (NCI), in the year 2020, the new cases of cancer that were expected to be diagnosed in the United States were about 1806590 cases. The statistics also stated that during the same year, 606520 people were expected to die as a result of the disease.

On the other hand, the liposome drug delivery market in Europe is projected to garner the second-largest revenue by the end of 2035. The market in the region is further segmented by country into Germany, France, United Kingdom, Italy, Spain, and the Rest of Europe. The market in Germany is projected to garner the second-largest revenue by the end of 2035. The market is driven by the increasing prevalence of chronic diseases such as cancer and cardiovascular diseases that require targeted drug delivery systems. Additionally, the rising demand for personalized medicine and the need for improved drug efficacy and safety are driving market growth.  The market for liposome delivery in Europe is highly regulated with stringent safety and efficacy guidelines. Companies operating in the market must comply with these regulations to obtain approval for their products. The European liposomal drug delivery market is expected to continue growing in the coming years, driven by increasing demand for targeted drug delivery systems and personalized medicine. 

Liposome drug delivery market in the Asia Pacific is anticipated to account for a significant market share by the end of 2035. The market is driven by the increasing prevalence of chronic diseases such as cancer and cardiovascular diseases that require targeted drug delivery systems. Additionally, the rising demand for personalized medicine and the need for improved drug efficacy and safety are driving market growth.  The Asia-Pacific liposome delivery market is expected to continue growing in the coming years, driven by increasing demand for targeted drug delivery systems and personalized medicine. Moreover, the development of new liposome technologies and growing interest in drug delivery in the pharmaceutical industry are expected to further drive market growth. 

/admin/report_image/Liposome Drug Delivery Market Size.PNG
Get more information on this report: Request Free Sample PDF

Top Featuring Companies Dominating the Global Liposome Drug Delivery Market

top-features-companies
    • Spectrum Pharmaceuticals, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Gilead Sciences, Inc.
    • Celsion Corporation
    • Ipsen Pharma
    • Pacira Pharmaceuticals, Inc.
    • Novartis AG
    • CordenPharma International
    • FUJIFILM Toyama Chemical Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Johnson & Johnson Services, Inc.

In-the-news

In The News

  • Endo Ventures Limited (EVL), a subsidiary of Endo International plc, agreed with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company, will commercialize his TLC product, TLC599, which is under investigation. TLC599 is an injectable compound in Phase III development for the treatment of knee osteoarthritis knee pain.
  • Pfizer and Acuitas Therapeutics entered into a Development and Options Agreement. This gives Pfizer the option to license Aquinas lipid nanoparticle (LNP) technology non-exclusively for up to 10 vaccine targets or therapeutics development. 

preview-analysis

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.


Author Credits:  Radhika Gupta, Shivam Bhutani


Key Questions Answered in the Report

1) What are the major factors driving the growth of the liposome drug delivery market?

Ans: The rising prevalence of cancer globally, and the increasing application of liposomes as a drug delivery system are some of the major factors anticipated to drive market growth.

2) What would be the CAGR of liposome drug delivery market over the forecast period?

Ans: The market size of capsaicin is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2023 – 2035.

3) What are the challenges affecting the liposome drug delivery market growth?

Ans: The high cost of development of the drug delivery system is one of the major factors estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of liposome drug delivery market in future?

Ans: North America is estimated to create notable growth opportunities for market growth over the forecast period.

5) Who are the major players dominating the liposome drug delivery market?

Ans: The major players in the market are Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., and Others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the liposome drug delivery market?

Ans: The market is segmented by application, product, technology, and by region.

8) Which segment captures the largest market size in product segment in the liposome drug delivery market?

Ans: The liposomal doxorubicin segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

 Request Free Sample Copy